CABA Cabaletta Bio Inc

$CABA the CEO really was impressive on today’s Morgan Stanley call. This is a MUST listen. Don’t rely on my summary or those of others. One of the things that was new and different from the data that’s been released so far is the CEO discussed the safety differences between the two big Pharma programs of CAR-T that were paused due to deaths and severe complications (including the Novartis program marred by 3 deaths from side effects) and RESE-CEL cell by CABA.  The CEO explained that the difference in safety originates from the length of manufacturing process. Apparently, the CAR-T therapies that resulted in very severe complications and deaths from these competing manufacturers involved manufacturing processes that were extremely short in duration - as short as two days - and apparently that truncated manufacturing produces cells that are much more likely to produce an inflammatory response and cause these kind of dangerous side effects. By contrast, RESE-CEL takes nine days to produce and as a result the cells are different and less likely to induce and inflammatory response. This CEO also made clear that some types of diseases are not likely to be subject to preconditioning while others are. The CEO again reiterated the company’s target of a BLA application for myositis, both for juveniles and adults, in the second half of 2027. He said they’re still working on the higher dose for PV without preconditioning and that the higher dose is likely needed to ensure a more durable and consistent response. He talked about the efficacy of the treatment in many of these autoimmune diseases and the numbers of people who basically were able to get off their steroids, and I believe the number was somewhere in the upper 80 percentile range for some diseases. As I recall, what the CEO said is that the biggest differentiator between RESE-CEL is safety.  he talked about the emphasis on safety with things like the longer manufacturing process and how they haven’t seen these deaths or ultra severe side effects in patients that brought the other two competitors’ trials to a pause. There was a lot of content and I’m only scratching the surface. It’s really a presentation every person must listen to themselves and do their own due diligence. Moreover, the CEO does a very good job at explaining technical concepts in simple to understand terms that people without significant medical training can grasp.  That is always the mark to me anyway, of a leader with both competence and confidence. Liars tend to hide in jargon. The bottom line is in 2027, there are going to be some very giant catalysts and it’s my personal opinion when those occur we will not see share prices anywhere near the high two dollar range. To me, $CABA is in the accumulation stage with the major catalysts a good deal in the future in 2027 so this is the time to accumulate (at least for me) but not expect to make a killing in the new term. Investing in this stock will require a little bit of patience, which is fine for my investing style. Nothing is certain in the stock market however and with a biotech like this, one big safety issue could sink the whole thing so I’m position sizing properly at 100,000 shares in relation to MY total portfolio.  If someone tells me they are full porting into this or any other development stage biotech I’d probably slap them silly (figuratively, of course). Good luck to the longs.

$CABA I got in. Great time now that the $2.50 warrant overhang got cleared. Main position always in $SLS and some in $OSTX . Sellas and OSTX is going to rocket first, but CABA seems solid. I've watched closely how devastating the autoimmune diseases can be. I'm not big in this, but I invested here for personal reasons and I hope it will succeed for the sake of patients.

$CABA $SLS $VSTM The Shorts deserve a punishment here honestly but we also know how this market game works! Just have a plan and don’t let them get your hard earned cash .

$CABA now announce a presentation for November and at that time reveal more solid Preconditioning free efficacy data. Back to $4. My personal prediction.

$CABA belongs over $5 already my opinion. Funded till commercialization. Revolutionary potential cure at Scale and with huge margins.

$CABA I cannot begin to imagine two stocks with more Explosive potential than Cabaletta Bio and $ALT Altimmune... $SPY

$CABA the right CAR-T tech is miraculous and safe and Caba is leading the way with Autoimmune Disease 🦠 It’s $BILLIONS and life saving potentially. The technology keeps working in cancer and our data is coming.

$CABA I bought 100,000 shares at an average of $2.74. It’s showing signs of bottoming and rising. Maybe it’ll go lower but it’s very very hard to time the exact bottom and when you make a mistake and try to get too greedy as to the exact bottom, you can get seriously burned if the stock boomerangs on you.  Quite happy with 100,000 shares of $2.74.

Why is $CABA about to run? There’s a huge divergence on 20 and 200 EMAs. RSI super low. Technicals are such that algos are picking this up and the run starts this week, even today. That yellow and blue line are absolutely too far away from eachother and they just can’t stretch any further. Warrants were priced at $2.50 so this is also very undervalued now. Amazing product too. Lots of reasons to reverse NOW! $PDSB $IBRX

$CABA We have passed the stage of high downward volume and are now in the stage where the stock remains stable with low volume. The next stage is for the price to rise with high volume. Just a little more patience. Naturally, this is a great opportunity for those who haven't entered CABA yet or have entered with a small capital.

$CABA no excuses. Everyone has had a chance to buy at these levels. I’m only up 16% now on a very large position, and I’ll ride it up and down. That’s how much confidence I have in this company. A big double-digit day is coming. In my opinion, CABA could be bought out at any time and jump to $15 overnight. 🔥

Guys you wanna check this company out too. This is one of the most advanced CAR-T companies getting ready to file a BLA this quarter as the first company ever with CAR-T on autoimmune diseases. I was bullish about $CABA, but Kyverna is way ahead. Technicals point to short term rise. $IBRX $CAPR $IOVA $PDSB

$CABA weak jobs report today Looks like that will put a stop to any future rate hikes That the Dems were hoping for lol The Fed has two mandates Full employment Price stability Will be talking about cutting rates next Specially, with an Iran deal All up from here for Small Caps I think we’ll finish strong today Doesn’t really matter to me this is a long hold When you lease expect it 💥   

$CABA I trust management to successfully convience the FDA that CABA doesn't need to increase its testing because another bio company had failed tests. CABA's testing will go on as planned. No stock dilution required.

$CABA I’ve seen this exact chart setup play out multiple times, and every time it led to the same result: a strong breakout.

$CABA warrants absorbed, interest rate hikes absorbed, hammer on the daily/weekly, bottom already hit, trading below institutional positions at cash valuation with no regards to the science and advancement this company has made, this reeks of a violent recovery + new 52 week highs coming off minor news, short positions have been thined out for a reason 🚀

$CABA $KYTX CABA data for DM and SLE is pretty good. But for gMG, KYTX has the best data Among all competitors.

$CABA 1–2 years ago I bought the stock at $2–2.5... and it hit a low of 1.3. I was patient, and suddenly it skyrocketed and kept climbing from there. This year the company is in a much better position. It has enough cash to last through all of 2027. It's just that a lot of things happened all at once: warrants, interest rate hikes, and the Novartis deaths, which might make it harder to recruit patients for clinical trials. I consider the rumors that FDA regulations might change unlikely. The stock has corrected significantly. Short sellers have likely increased since the September 15 report. And today/yesterday was the last day for institutional investors to exit due to the end of the quarter. I believe starting today an upward trend will begin over the coming days, so the bottom has likely been reached. By the end of the year, the stock will be at $4–$5.

$CABA great news folks. Company just filed a K a moment ago warrants have all been exercised company has raised $128.2 million for continuing operations. Now we moon. Set forth below is the screenshot from the 8K and I’ll quote the operative language immediately below: “In connection with Cabaletta Bio’s (the “Corporation”) June 2025 underwritten public offering, the Corporation issued 53,090,190 common stock warrants (the “Common Stock Warrants”) that had an exercise price of $2.50 per whole share of its common stock and an expiration date of September 12, 2026 (the “Expiration Date”). From issuance through June 30, 2026, 5,275,100 Common Stock Warrants were exercised resulting in aggregate gross proceeds of approximately $13.2 million. From July 1, 2026 through the Expiration Date, 46,011,900 Common Stock Warrants were exercised resulting in aggregate gross proceeds of approximately $115.0 million. The aggregate gross proceeds from exercises of the Common Stock Warrants from issuance through the Expiration Date is approximately $128.2 million.” Let’s go!

$CABA Cellares and Sonoma CEOs are both presenting with Caba today ref ex-vivo presentation. Could be meaningful as they are the 2 companies Caba have deals with to scale delivery